SynthesisFrontiers in medicine2026
Global research landscape and thematic transitions in pyruvate kinase deficiency: a decadal bibliometric analysis (2015-2025).
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pyruvate kinase deficiency (PKD) is the most common cause of congenital non-spherocytic hemolytic anemia. This study systematically maps the scholarly output and evolving research trends in PKD over the past decade (2015-2025) to identify core contributors and track thematic trajectories. Methods: Bibliographic records were retrieved from the Web of Science Core Collection (WoSCC) and analyzed quantitatively using CiteSpace, VOSviewer, and R-bibliometrix. To control for potential selection bias, a parallel supplementary search was conducted in PubMed and Scopus using identical query strings. PubMed yielded 15 unique non-overlapping eligible records, whereas Scopus returned 0. Given metadata disparities and small sample limits, these records were dedicated exclusively to exploratory qualitative thematic concordance verification rather than statistical network synthesis. Results: The primary WoSCC network isolated 90 core publications derived from 649 initial records after rigorous screening. Multi-database cross-validation confirmed a stable thematic alignment. Manual textual extraction of the 15 external PubMed records displayed precise semantic resonance with the core dataset's clusters, tracking a clear focus transition from baseline genotype mapping to targeted pyruvate kinase, R-type (PKR) activators (specifically mitapivat) and preclinical gene-editing interventions, without introducing divergent thematic anomalies. Conclusion: The analytical framework indicates that the PKD research domain is characterized by an evolving therapeutic focus, progressing from foundational descriptive epidemiology and supportive care toward mechanism-based, targeted interventions. Current empirical evidence highlights PKR allosteric activation as the most clinically developed cluster, while gene therapy represents an active, early-stage investigational frontier.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.